Tissue Regenix Group PLC (LSE: TRX) is a regenerative medical devices company developing and commercialising tissue-based products for wound care, orthopaedics, and dental markets. Its proprietary decellularisation technology enables biologic implants with reduced rejection risk. With a growing presence in the US and strategic partnerships in place, Tissue Regenix offers long-term exposure to the bio-implants and regenerative medicine space.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.78% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Ratings and Reviews
Ratings and Reviews
